Multiple affiliate sales and option exercises at Mineralys Therapeutics (MLYS)

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. reported affiliated sales of common stock via Form 144, showing multiple dispositions through broker-assisted and cash transactions. The excerpt lists individual sales by David Rodman between 02/09/2026 and 05/12/2026, and shows an exercise-related transfer on 05/13/2026.

Key Figures

Shares outstanding: 82,498,101 Exercise (broker-assisted cashless): 7,707 shares Sale on 05/12/2026: 6,348 shares +2 more

5 metrics

Shares outstanding 82,498,101 as of 05/13/2026 (securities information line)

Exercise (broker-assisted cashless) 7,707 shares Exercise of employee stock options on 05/13/2026

Sale on 05/12/2026 6,348 shares Common Stock sale by David Rodman, gross proceeds $186,348.35

Sale on 05/11/2026 2,171 shares Common Stock sale by David Rodman, gross proceeds $64,500.41

Sale on 02/16/2026 14,055 shares Common Stock sale by David Rodman, gross proceeds $385,732.29

Key Terms

broker assisted cashless exercise, Form 144, exercise of employee stock options

3 terms

broker assisted cashless exercise financial

"Common stock | 05/13/2026 | Exercise of employee stock options | ... | 7707 | 05/13/2026 | Broker assisted cashless exercise"

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

exercise of employee stock options financial

"Common stock | 05/12/2025 | Exercise of employee stock options"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	14056	401789.92	82498101	05/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	05/13/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			7707	05/13/2026	Broker assisted cashless exercise
Common stock	12/11/2024	Exercise of employee stock options	Mineralys Therapeutics, Inc.			3	12/11/2024	Cash
Common stock	05/12/2025	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6346	05/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/09/2026	2171	65585.91
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/12/2026	6349	184076.52
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/16/2026	14055	385732.29
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/17/2026	417	11505.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/09/2026	2171	58269.64
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/12/2026	6348	173748.15
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/13/2026	14058	369225.07
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/17/2026	417	10696.05
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	04/09/2026	2170	59414.60
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	04/13/2026	14058	373086.81
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	04/15/2026	6348	175585.68
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	04/17/2026	416	13033.28
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	05/11/2026	2171	64500.41
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	05/12/2026	6348	186348.35

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Mineralys Therapeutics (MLYS) Form 144 show about recent transactions?

The filing lists multiple common stock dispositions by an affiliate, including sales dated 02/09/2026 through 05/12/2026. The entries show share counts and gross proceeds for each trade, with broker-assisted and cash methods noted.

How many shares and proceeds were reported on the 05/12/2026 sale in MLYS?

The entry dated 05/12/2026 reports a sale of 6,348 shares with gross proceeds of $186,348.35. The line lists the security as Common Stock and the seller as David Rodman.

Does the Form 144 excerpt show stock option exercises for MLYS?

Yes. The excerpt lists exercises of employee stock options, including an entry on 05/13/2026 described as a broker assisted cashless exercise for 7,707 shares and earlier cash exercises on other dates.

Who is the primary seller listed in the MLYS Form 144 excerpt?

The repeated selling party shown is David Rodman at the Radnor, PA address. Multiple sale dates list his name alongside share counts and gross proceeds in the excerpt.

What baseline share count appears in the excerpt for Mineralys Therapeutics (MLYS)?

The excerpt includes the figure 82,498,101 paired with the date 05/13/2026, presented in the securities information section. The line pairs that number with the NASDAQ listing.